Home/Rare Diseases/Thalassemia

Blood & Immune

Thalassemia

Also called beta thalassemia, alpha thalassemia, thalassaemia, Cooley's anemia

Thalassemia is an autosomal recessive hemoglobinopathy caused by mutations in genes encoding alpha or beta globin chains, resulting in reduced or absent hemoglobin production. The imbalance of globin chains causes hemolysis (destruction of red blood cells) and ineffective erythropoiesis (impaired red blood cell production).

...active trials

Live from ClinicalTrials.gov

View trials below

About trials for Thalassemia

Gene therapy for thalassemia has shown remarkable success in clinical trials, with many patients achieving complete hematologic correction and elimination of transfusion dependence. The FDA has approved CTX001, a lentiviral vector-based gene therapy for beta-thalassemia major.

Try Match Me →

About Thalassemia

Thalassemia is an autosomal recessive hemoglobinopathy caused by mutations in genes encoding alpha or beta globin chains, resulting in reduced or absent hemoglobin production. The imbalance of globin chains causes hemolysis (destruction of red blood cells) and ineffective erythropoiesis (impaired red blood cell production). In beta-thalassemia major, the most severe form, hemoglobin production is virtually absent, resulting in severe hemolytic anemia requiring regular blood transfusions to maintain acceptable hemoglobin levels. Chronic transfusion leads to iron overload, causing organ damage (cirrhosis, cardiomyopathy, endocrine dysfunction). Extramedullary hematopoiesis (blood production outside the bone marrow) causes hepatosplenomegaly and bone expansion with characteristic facial deformities. Without transfusion and iron chelation therapy, death typically occurs in childhood. Alpha-thalassemia has variable presentations depending on the number of alpha-globin genes deleted.

Common Symptoms

  • Severe anemia and fatigue
  • Jaundice from hemolysis
  • Bone pain and deformities from extramedullary hematopoiesis
  • Hepatosplenomegaly
  • Heart problems from iron overload
  • Growth delay and delayed puberty

Who It Affects

Symptoms of beta-thalassemia major typically emerge after age 6 months. Inherited as autosomal recessive. Most common in people of Mediterranean, North African, Middle Eastern, and Asian descent.

Getting Involved in Clinical Trials

Gene therapy for thalassemia has shown remarkable success in clinical trials, with many patients achieving complete hematologic correction and elimination of transfusion dependence. The FDA has approved CTX001, a lentiviral vector-based gene therapy for beta-thalassemia major. Luspatercept, an erythroid maturation agent, has also shown benefit in reducing transfusion dependence. The Thalassemia International Federation and patient organizations maintain comprehensive trial information. If you have thalassemia major, discuss with your hematologist about whether you are a candidate for gene therapy or other emerging therapies. Genetic counseling is recommended for affected individuals and families. Current standard care includes transfusion therapy, iron chelation, and monitoring for complications.

Trusted Sources

Active Clinical Trials for Thalassemia

Finding trials for Thalassemia...

Related Blood & Immune Conditions

Blood & Immune

Sickle Cell Disease

Sickle cell disease is an inherited blood disorder where hemoglobin polymerizes under low oxygen, causing red blood cell...

Blood & Immune

Severe Combined Immunodeficiency

Severe combined immunodeficiency is a rare genetic disorder affecting both T cell and B cell immune function, resulting ...

Blood & Immune

Mastocytosis

Mastocytosis is a rare hematological disorder characterized by clonal expansion of mast cells in bone marrow, organs, an...